Atara, Pierre Fabre's cell therapy to get another shot at FDA approval
Max Gelman / endpoints - There's new life for a twice-rejected T cell therapy from Atara Biotherapeutics and Pierre Fabre Pharmaceuticals. US regulators are willing to reconsider using a Phase 3 study as the basis for an approval, Atara said ...
AI Summary: Regulators have agreed to re-examine a previously rejected cell‑therapy application for a rare lymphoma, giving the Atara‑Pierre Fabre program another opportunity at approval. The decision follows additional data and stakeholder engagement, offering the developer a second bite at the apple and patients a renewed, if cautious, hope for a novel treatment pathway.
Related Stories
FDA approves Replimune’s Tudriqev after repeated rejections / 22 days
FDA clears pivekimab sunirine (Decnupaz) as first BPDCN ADC / 3 months
FDA advisory panel rejects camizestrant after SERENA‑6 results / 3 months
Bristol Myers Squibb wins first-in-class approval for protein‑degrader myeloma therapy / 15 days
Belzutifan plus pembrolizumab gains approval for adjuvant RCC / 5 wks
FDA greenlights datopotamab deruxtecan for metastatic TNBC / 2 months
FDA approves belzutifan (Welireg) plus pembrolizumab for adjuvant RCC / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Vaccine Safety, Supply Chain, Obesity, Mergers and Acquisitions and look for the RSS link.
StackHealth Time Machine